Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q3 2016 · 10-Q
Revenue$0.00$0.00— vs Q3 2015 Net Income-$3.63M-$3.63MN/M vs Q3 2015 EPS Diluted$0.13$0.13−81.7% vs Q3 2015 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
-$2,530,000
N/M
Operating Cash Flowderived-$563,000N/M ended Sep 30, 2016 · filed Nov 14, 2016 · 45 d after period end